



PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 9

Complete if Known

Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Schenk, D. B.
Art Unit	1647
Examiner Name	Turner, S. L.
Attorney Docket Number	15270J-004740US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	578	6,875,434	04-05-2005	Schenk	
	577	6,866,849	03-15-2005	Schenk	
	575	6,866,850	03-15-2005	Schenk	
	576	6,818,218	11-16-2004	Schenk	
	563	6,787,637	09-07-2004	Schenk et al.	
	562	6,750,324	06-15-2004	Schenk et al.	
	442	6,713,450 B2	03-30-2004	Frangione et al.	
	444	2004/0043418 A1	03-04-2004	Holtzman et al.	
	415	2003/0166558 A1	09-04-2003	Frangione et al.	
	431	2003/0165496 A1	09-04-2003	Basi et al.	
	544	2003/0147882 A1	08-07-2003	Solomon et al.	
	432	6,562,341 B2	05-13-2003	Prusiner et al.	
	440	2003/0068316 A1	04-10-2003	Klein et al.	
	453	2002/0058267 A1	05-16-2002	Ozenberger et al.	
	511	6,331,440	12-18-2001	Nordstedt, et al.	
	416	6,303,567 B1	10-16-2001	Findeis et al.	
	516	6,261,569	07-17-2001	Comis et al.	
	452	6,218,506 B1	04-17-2001	Krafft et al.	
	510	6,022,859	02-08-2000	Kiessling, et al.	
	417	5,985,242	11-16-1999	Findeis et al.	
	512	5,891,991	04-06-1999	Wasco et al.	
	445	5,854,215	12-29-1998	Findeis et al.	
	446	5,817,626	10-06-1998	Findeis et al.	
	451	5,766,846	06-16-1998	Schlossmacher et al.	
	515	5,652,334	07-29-1997	Roberts	
	513	5,514,548	05-07-1996	Krebber et al.	
	514	5,470,951	11-28-1995	Roberts	
	543	5,278,049	01-11-1994	Baker et al.	
	548	5,096,706	03-17-1992	Flint	
	570	4,912,206	03-27-1990	Goldgaber et al.	

Examiner
Signature

Date
Considered

10-27-05

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
60479202 v1

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Schenk, D. B.
Art Unit	1647
Examiner Name	Turner, S. L.
Attorney Docket Number	15270J-004740US

Sheet 2 of 9

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	533	AU	199870091		07-01-1999			
	523	EP	752 886	B1	01-28-1998			
	579	WO	04/031400	A2	04-15-2004			
	571	WO	04/13172	A2, A3	02-12-2004			
	441	WO	03/104437	A2	12-18-2003			
	443	WO	03/074081	A1	09-12-2003			
	447	WO	03/051374	A2	06-26-2003			
	433	WO	03/020212	A2	03-13-2003			
	458	WO	02/060481	A1	08-08-2002			
	457	WO	02/046237	A1	06-13-2002			
	557	WO	02/88307	A2	11-07-2002			
	556	WO	02/88306	A2	11-07-2002			
	456	WO	02/021141	A2	03-14-2002			
	450	WO	01/18169	A3	03-15-2001			
	455	WO	01/10900	A2	02-15-2001			
	529	WO	00/68263	A2	11-16-2000			
	519	WO	00/26238	A2	05-11-2000			
	555	WO	00/23082	A1	04-27-2000			
	522	WO	00/20027	A2	04-13-2000			
	526	WO	99/06587	A2	02-11-1999			
	454	WO	98/33815	A1	08-06-1998			
	520	WO	98/22120	A1	05-28-1998			
	530	WO	98/08868	A1	03-05-1998			
	521	WO	98/05350	A1	02-12-1998			
	525	WO	98/02462	A1	01-22-1998			
	527	WO	97/32017	A1	09-04-1997			
	528	WO	97/08320	A1	03-06-1997			
	532	WO	96/37621	A2	11-28-1996			
	518	WO	95/23166	A1	08-31-1995			
	531	WO	95/08999	A1	04-06-1995			
	524	WO	95/05393	A2	02-23-1995			
	517	WO	94/05311	A1	03-17-1994			

Examiner
SignatureDate
Considered

10-27-05

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
60479202 v1

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/322,289
		Filing Date	May 28, 1999
		First Named Inventor	Schenk, D. B.
		Art Unit	1647
		Examiner Name	Turner, S. L.
(use as many sheets as necessary)		Attorney Docket Number	15270J-004740US
Sheet	3	of	9

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SP	448	ANDREW et al., <i>Current Protocols in Immunology</i> , 2.7.1-2.9.8, John Wiley & Sons, Inc. (1997).	
	484	ARENDIASH et al., "Behavioral assessment of Alzheimer's transgenic mice following long-term A β vaccination: Task specificity and correlations between A β deposition and spatial memory," <i>DNA and Cell Biology</i> , 20(11):737-744 (2001).	
	485	BACSKAI et al., "Imaging of amyloid- β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy," <i>Nature Medicine</i> , 7(3):369-372 (2001).	
	504	BALBACH et al., "Amyloid fibril formation by A β ₁₆₋₂₂ , a seven-residue fragment of the Alzheimer's β -amyloid peptide, and structural characterization by solid state NMR," <i>Biochemistry</i> , 39:13748-13759 (2000).	
	550	BARD et al., "Epitope and isotype specificities of antibodies to β -amyloid peptide for protection against Alzheimer's disease-like neuropathology," <i>PNAS</i> , 100(4):2023-2028 (2003).	
	561	BELLOTTI et al., "Application of Monoclonal Anti-idiotypes in the Study of AL Amyloidosis: Therapeutic Implications," <i>Renal Failure</i> , 15(3):365-371 (1993).	
	558	BENJAMINI et al., from <i>IMMUNOLOGY A Short Course</i> , Second Edition, pages 136-138, 143, 73-74, 372-373, and 400-401, 1991, published by Wiley-Liss, Inc., New York, New York.	
	540	BENKIRANE, et al., "Antigenicity and Immunogenicity of Modified Synthetic Peptides Containing D-Amino Acid Residues," <i>J. Biol. Chem.</i> , 268(23):26279-26285 (1993).	
	419	BORK et al., "Go hunting in sequence databases but watch out for the traps," <i>Trends in Genetics</i> , 12(10):425-427 (1996).	
	418	BORK, P., "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle," <i>Genome Research</i> , 10:398-400 (2000).	
SP	420	BRENNER, S. E., "Errors in genome annotation," <i>Trends in Genetics</i> , 15(4):132-133 (1999).	
	461	BURDICK et al., "Assembly and aggregation properties of synthetic Alzheimer's A β amyloid peptide antigens," <i>J. Biol. Chem.</i> , 267:546-555 (1992).	
	421	CASTILLO et al., "Amylin / Islet Amyloid Polypeptide: Biochemistry, Physiology, Patho-Physiology," <i>Diabete & Metabolisme (Paris)</i> , 21:3-25 (1995).	
	542	CHISHTI et al., "Early-onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695," <i>J. Biol. Chem.</i> , 276(24):21562-70 (2001).	

Examiner Signature	<i>Shen Dan</i>	Date Considered	10-27-05
--------------------	-----------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/322,289
		Filing Date	May 28, 1999
		First Named Inventor	Schenk, D. B.
		Art Unit	1647
		Examiner Name	Turner, S. L.
Sheet 4 of 9	Attorney Docket Number	15270J-004740US	

566	CHOTHIA et al., "Domain Association in Immunoglobulin Molecules," <u>J. Mol. Biol.</u> , 186:651-663 (1985).
509	CIRRITO et al., "Amyloid β and Alzheimer disease therapeutics: the devil may be in the details," <u>J. Clin. Invest.</u> , 112:321-323 (2000).
462	CO et al., "Chimeric and humanized antibodies with specificity for the CD33 antigen," <u>J. Immunol.</u> , 148:1149-1154 (1992).
541	CRIBBS et al., "All-D-Erantomers of Beta-Amyloid Exhibit Similar Biological Properties to All-L-Beta-Amyloids," <u>J. Biol. Chem.</u> , 272:7431-7436 (1997).
412	DAS et al., "Amyloid- β Immunization Effectively Reduces Amyloid Deposition in FcR γ Knock-Out-Mice," <u>J. Neuroscience</u> , 23(24):8532-8538 (2003).
469	DEMATOS et al., "Peripheral anti-A β antibody alters CNS and plasma clearance and decreases A β burden in a mouse model of Alzheimer's disease," <u>PNAS</u> , 98(15):8850-8855 (2001).
493	DEMATOS et al., "Plaque-associated disruption of CSF and plasma amyloid- β (A β) equilibrium in a mouse model of Alzheimer's disease," <u>J. Neurochem.</u> , 81:229-236 (2002).
486	DICKEY et al., "Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated β -amyloid 1-42 peptide," <u>DNA and Cell Biology</u> , 20(11):723-729 (2001).
436	DICKSON et al., "Neuroimmunology of Alzheimer's disease: a conference report," <u>Neurobiology of Aging</u> , 13(6):793-798 (1992), abstract only
422	DOERKS et al., "Protein annotation: detective work for function prediction," <u>Trends in Genetics</u> , 14(6):248-250 (1998).
407	ECK et al., <i>Goodman and Gilman's The pharmacological basis of therapeutics</i> , Chapter 5, pages 77-101 (1996).
475	EL-AGNAF et al., "The influence of the central region containing residues 19-25 on the aggregation properties and secondary structure of Alzheimer's beta-amyloid peptide," <u>Eur. J. Biochem.</u> , 256(3):560-569 (1998).
501	ESLER et al., "Point substitution in the central hydrophobic cluster of a human β -amyloid congener disrupts peptide folding and abolishes plaque competence," <u>Biochemistry</u> , 35:13914-13921 (1996).
539	FINDEIS et al., "Modified peptide inhibitors of amyloid B-peptide polymerization," <u>Biochemistry</u> , 38:6791-6800 (1999).
464	FLOOD et al., "An amyloid β -Protein fragment, A β [12-28], equipotently impairs post-training memory processing when injected into different limbic system structures," <u>Brain Res.</u> , 663(2):271-276 (1994).
538	FLOOD, et al., "Topography of a binding site for small amnesic peptides deduced from structure-activity studies: Relation to amnesic effect of amyloid B protein," <u>PNAS</u> , 91:380-384 (1994).

Examiner Signature	<i>Shen Zhen</i>	Date Considered	10-27-05
--------------------	------------------	-----------------	----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60479202 v1

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 9

Complete if Known

Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Schenk, D. B.
Art Unit	1647
Examiner Name	Turner, S. L.
Attorney Docket Number	15270J-004740US

80	423	FONSECA et al., "The Presence of Isoaspartic Acid In β -Amyloid Plaques Indicates Plaque Age," <u>Experimental Neurology</u> , 157(2):277-288 (1999).	
	565	FRAZER et al., "Immunoglobulins: Structure and Function," chapter 3, pages 37-74 from <i>Fundamental Immunology</i> , fourth edition, W.E. Paul, eds., Lippincott-Raven publishers, Philadelphia (1999).	
	463	GHISO et al., "Epitope map of two polyclonal antibodies that recognize amyloid lesions in patients with Alzheimer's disease," <u>Biochem. J.</u> , 282 (Pt 2):517-522 (1992).	
	470	GIULIAN et al., "Specific domains of β -amyloid from Alzheimer plaque elicit neuron killing in human microglia," <u>J. Neurosci.</u> , 16 (19):6021-6037 (1996).	
	424	GOLDSBY et al., "Vaccines," Chapter 18 from <i>Immunology</i> , 4th Edition, W.H. Freeman and Company, New York, pages 449-465 (2000).	
	503	GOREVIC et al., "Ten to fourteen residue peptides of Alzheimer's disease protein are sufficient for amyloid fibril formation and its characteristic X ray diffraction pattern" <u>Biochem. and Biophys. Res. Commun.</u> , 147(2):854-862 (1987).	
	487	HAASS et al., "Protofibrils, the unifying toxic molecule of neurodegenerative disorders?," <u>Nature Neuroscience</u> , 4(9):859-860 (2001).	
	476	HE et al., "Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P- selectin," <u>J. Immunol.</u> , 160:1029-1035 (1998).	
	559	HERLYN et al., "Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma," <u>Eur. J. Immunol.</u> , 9:657-659 (1979).	
	473	HILBICH et al., "Aggregation and secondary structure of synthetic amyloid β A4 peptides of Alzheimer's disease," <u>J. Mol. Biol.</u> , 218:149-163 (1991).	
	471	HILBICH et al., "Substitutions of hydrophobic amino acid reduce the amyloidogenicity of Alzheimer's disease β A4 peptides" <u>J. Mol. Biol.</u> , 228:460-473 (1992).	
	534	HOCK et al., "Antibodies against β -Amyloid Slow Cognitive Decline in Alzheimer's Disease," <u>Neuron</u> , 38:542-554 (2003).	
	413	HOLTZMAN et al., "A β immunization and anti-A β antibodies: potential therapies for the prevention and treatment of Alzheimer's disease," <u>Advanced Drug Delivery Reviews</u> , 54:1603-1613 (2002).	
	546	IRIZARRY et al., "A β Deposition is Associated with Neuropil Changes, but not with Overt Neuronal Loss in the Human Amyloid Precursor Protein V717F (PDAPP) Transgenic Mouse," <u>J. Neuroscience</u> , 17(18):7053-7059 (1997).	
	560	JAHLING et al., "Opsonization of Alphaviruses in Hamsters," <u>J. Medical Virology</u> , 12:1-16 (1983).	
80	449	JOHNSON-WOOD et al., "Amyloid precursor protein processing and A β_{42} deposition in a transgenic mouse model of Alzheimer disease," <u>PNAS</u> , 94:1550-1555 (1997).	

Examiner
Signature

Sham Turner

Date
Considered

10-27-05

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60479202 v1

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/322,289
		Filing Date	May 28, 1999
		First Named Inventor	Schenk, D. B.
		Art Unit	1647
		Examiner Name	Turner, S. L.
(use as many sheets as necessary)		Attorney Docket Number	15270J-004740US
Sheet	6	of	9

547	KAYED et al., "Conformational Transitions of Islet Amyloid Polypeptide (IAPP) in Amyloid Formation <i>In Vitro</i> ," <u>J. Mol. Biol.</u> , 287:781-796 (1999).
434	KELLY, J. W., "Alternative conformations of amyloidogenic proteins govern their behavior," <u>Current Opinion in Structural Biology</u> , 6:11-17 (1996).
554	KETTLEBOROUGH et al., "Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation," <u>Protein Engineering</u> , 4(7):773-783 (1991).
488	KLEIN et al., "Targeting small A β oligomers: the solution to an Alzheimer's disease conundrum?," <u>Trends in Neurosciences</u> , 24(4):219-224 (2001).
494	KOTILINEK et al., "Reversible memory loss in a mouse transgenic model of Alzheimer's disease," <u>J. Neurosci.</u> , 22(15):6331-6335 (2002).
465	KOUDINOV et al., "The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma," <u>Biochem. & Biophys. Res. Comm.</u> , 205:1164-1171 (1994).
478	KUO et al., "High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease," <u>Biochem. Biophys. Res. Comm.</u> , 257(3):787-791 (1999).
477	LAMBERT et al., "Diffusible, nonfibrillar ligands derived from A β 1-42 are potent central nervous system neurotoxins," <u>PNAS</u> , 95:6448-6453 (1998).
489	LAMBERT et al., "Vaccination with soluble A β oligomers generates toxicity-neutralizing antibodies," <u>J. Neurochem.</u> , 79:595-605 (2001).
490	LEE et al., "A β immunization: Moving A β peptide from brain to blood," <u>PNAS</u> , 98(16):8931-8932 (2001).
553	LEMERE et al., "Intranasal immunotherapy for the treatment of Alzheimer's disease: <i>Escherichia coli</i> LT and LT(R192G) as mucosal adjuvants," <u>Neurobiology of Aging</u> , 23(6):991-1000 (2002).
551	LEVERONE et al., "A β 1-15 is less immunogenic than A β 1-40/42 for intranasal immunization of wild-type mice but may be effective for boosting," <u>Vaccine</u> , 21:2197-2206 (2003).
459	LEVITT, M., "Molecular dynamics of native protein," <u>J. Mol. Biol.</u> , 168:595-620 (1983).
481	LEVY et al., "Immunization for Alzheimer's disease: A shot in the arm or a whiff?," <u>American Neurological Assoc.</u> , 48:553-554 (2000).
499	LUE et al., "Soluble β -amyloid Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease," <u>Am. J. Pathol.</u> , 155:853-862 (1999).
502	MAGGIO et al., "Brain Amyloid - A Physicochemical Perspective," <u>Brain Pathology</u> , 6:147-162 (1996).
408	MARSHALL, E., "Gene Therapy's Growing Pains," <u>Science</u> , 269:1050-1055 (1995).

Examiner
Signature*Shen Shen*Date
Considered

10-27-05

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60479202 v1

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/322,289
		Filing Date	May 28, 1999
		First Named Inventor	Schenk, D. B.
		Art Unit	1647
		Examiner Name	Turner, S. L.
Sheet 7 of 9	Attorney Docket Number	15270J-004740US	

545	MASLIAH et al., "Comparison of Neurodegenerative Pathology in Transgenic Mice Overexpressing V717F β -Amyloid Precursor Protein and Alzheimer's Disease," <u>J. Neuroscience</u> , 16(18):5795-5811 (1996).
479	MCLEAN et al., "Soluble pool of A β amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease," <u>Amer. Neurological Assoc.</u> , 46:860-866 (1999).
439	NALBANTOGLU, J., "Beta-amyloid protein in Alzheimer's disease," <u>Can. J. Neurol. Sci.</u> , 18(3 suppl.):424-427 (1991), abstract only
482	NASLUND et al., "Correlation between elevated levels of amyloid β peptide in the brain and cognitive decline," <u>J. Am. Med. Assoc.</u> , 283:1571 (2000).
425	NGO et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," pages 492-495 from Chapter 14 of <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , Merz et al., eds., Birkhauser Boston (1994).
568	NOVOTNY et al., "Structural invariants of antigen binding: Comparison of immunoglobulin V _L -V _H and V _L -V _L domain dimmers," <u>PNAS</u> , 82:4592-4596 (1985).
409	ORKIN et al., <i>Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy</i> , December 7, 1995
564	PCT Search Report of 12/14/04 for application PCT/US04/02856
437	PERSSON et al., "IgG subclass-associated affinity differences of specific antibodies in humans," <u>J. Immunology</u> , 140(11):3875-3879 (1988), abstract only
491	PODUSLO et al., "Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease," <u>Neurobiol. Dis.</u> , 8(4):555-567 (2001).
460	QUEEN et al., "A humanized antibody that binds to the interleukin 2 receptor," <u>PNAS</u> , 86:10029-10033 (1989).
497	RAGUSI et al., "Redistribution of Imipramine from Regions of the Brain Under the Influence of Circulating Specific Antibodies," <u>J. Neurochem.</u> , 70(5):2099-2105 (1998).
414	SCHENK, D., "Amyloid- β immunotherapy for Alzheimer's disease: the end of the beginning," <u>Nature Reviews</u> , 3:824-828 (2002).
466	SCHWARZMAN et al., "Transthyretin sequesters amyloid β protein and prevents amyloid formation," <u>PNAS</u> , 91:8368-8372 (1994).
536	SELA et al., "Different roles of D-amino acids in immune phenomena," <u>FASEB J.</u> , 11(6):449-456 (1999)..

Examiner Signature		Date Considered	10-27-05
--------------------	---	-----------------	----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60479202 v1

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/322,289
		Filing Date	May 28, 1999
		First Named Inventor	Schenk, D. B.
		Art Unit	1647
		Examiner Name	Turner, S. L.
Sheet 8 of 9	Attorney Docket Number	15270J-004740US	

552	SIGURDSSON et al., "Immunization with a Nontoxic/Nonfibrillar Amyloid- β Homologous Peptide Reduces Alzheimer's Disease-Associated Pathology in Transgenic Mice," <u>Am. J. Pathology</u> , 159(2):439-447 (2001).	
505	SIMMONS, L., "Secondary structure of amyloid β peptide correlates with neurotoxic activity <i>in vitro</i> ," <u>Molecular Pharmacology</u> , 45:373-379 (1994).	
426	SINGH, K. S., "Neuroautoimmunity: Pathogenic Implications for Alzheimer's Disease," <u>Gerontology</u> , 43:79-94 (1997).	
438	SINGH, V. K., "Studies of neuroimmune markers in Alzheimer's disease," <u>Mol. Neurobiology</u> , 9(1-3):73-81 (1994), abstract only	
427	SMITH et al., "The challenges of genome sequence annotation or 'The devil is in the details,'" <u>Nature Biotechnology</u> , 15:1222-1223 (1997).	
411	SOLOMON et al., "The Amino Terminus of the β -Amyloid Peptide Contains an Essential Epitope for Maintaining Its Solubility," from <i>Progress in Alzheimer's and Parkinson's Diseases</i> , edited by Fisher et al., Plenum Press, New York, pages 205-211 (1995).	
549	SOLOMON, B., "Immunological approaches as therapy for Alzheimer's disease," <u>Expert Opin. Biol. Ther.</u> , 2(8):907-917 (2002).	
508	SOTO et al., "The α -helical to β -strand transition in the amino-terminal fragment of the amyloid β -peptide modulates amyloid formation," <u>J. Biol. Chem.</u> , 270(7):3063-3067 (1995).	
435	STERN et al., "Antibodies to the β -amyloid peptide cross-react with conformational epitopes in human fibrinogen subunits from peripheral blood," <u>FEBS Letters</u> , 264(1):43-47 (1990).	
496	STRBAK et al., "Passive Immunization and Hypothalamic Peptide Secretion", <u>Neuroendocrinology</u> , 58:210-217 (1993).	
498	SUO et al., "Soluble Alzheimers β -amyloid constricts the cerebral vasculature in vivo" <u>Neuroscience Letters</u> , 257:77-80 (1998).	
467	TABATON et al., "Soluble amyloid β -protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid," <u>Biochem. and Biophys. Res. Comm.</u> , 200(3):1598-1603 (1994).	
472	TELLER et al., "Presence of soluble amyloid β -peptide precedes amyloid plaque formation in Down's syndrome" <u>Nature Medicine</u> , 2(1):93-95 (1996).	
500	TJERNBERG et al., "A molecular model for Alzheimer amyloid β -peptide fibril formation," <u>J. Biol. Chem.</u> , 274(18):12619-12625 (1999).	
537	TJERNBERG, et al., "Controlling amyloid beta-peptide fibril formation with protease-stable ligands," <u>J. Biol. Chem.</u> , 272(19):12601-12605 (1997).	
492	TOWN et al., "Characterization of murine immunoglobulin G antibodies against human amyloid- β_{1-42} " <u>Neurosci. Lett.</u> , 307:101-104 (2001).	

Examiner
SignatureDate
Considered

10-27-05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60479202 v1

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/322,289
		Filing Date	May 28, 1999
		First Named Inventor	Schenk, D. B.
		Art Unit	1647
		Examiner Name	Turner, S. L.
Sheet 9 of 9	Attorney Docket Number	15270J-004740US	

535	VAN REGENMORTEL et al, "D-peptides as immunogens and diagnostic reagents," <u>Curr. Opin. Biotechnol.</u> , 9(4):377-382 (1998).	
428	VELAZQUEZ et al., "Aspartate residue 7 in amyloid β -protein is critical for classical complement pathway activation: Implications for Alzheimer's disease pathogenesis," <u>Nature Medicine</u> , 3(1):77-79 (1997).	
410	VERMA et al., "Gene therapy - promises, problems and prospects," <u>Nature</u> , 389:239-242 (1997).	
569	VERSHIGORA A. E. OSHCHAYA IMMUNOLOGIYA, pages 35, 229-231 and 152-153.	
480	WANG et al., "The levels of soluble versus insoluble brain A β distinguish Alzheimer's disease from normal and pathologic aging," <u>Experimental Neurology</u> , 158:328-337 (1999).	
495	WANG et al., "Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus," <u>Brain Research</u> , 924:133-140 (2002).	
429	WELLS, J. A., "Additivity of Mutational Effects in Proteins," <u>Biochemistry</u> , 29(37):8509-8517 (1990).	
474	WINTER et al., "Humanized antibodies" <u>Immunology Today</u> , 14(6):243-246 (1996).	
468	WISNIEWSKI et al., "Alzheimer's disease and soluble A beta," <u>Neurobiol. Aging</u> , 15(2):143-52 (1994).	
506	WOOD et al., "Prolines and amyloidogenicity in fragments of the Alzheimer's peptide β /A4" <u>Biochemistry</u> , 34:724-730 (1995).	
567	WU et al., "An Analysis of the Sequences of the Variable Regions of Bence Jones Proteins and Myeloma Light Chains and their Implications for Antibody Complementarity," <u>J. Exp. Med.</u> , 132:211-250 (1970).	
507	XU et al., "Increased incidence of anti- β -amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease," <u>Mechanisms of Ageing and Development</u> , 94:213-222 (1997).	
430	YANG et al., "Effects of Racemization on the Aggregational Properties of the Amyloid β -Peptide in Alzheimer's Disease," abstract # 255 from American Chemical Society 214th National Meeting (1997).	
483	ZLOKOVIC et al., "Clearance of amyloid β -peptide from brain: transport or metabolism?," <u>Nature Medicine</u> , 6(7):718-719 (2000).	

Examiner Signature		Date Considered	10-27-05
--------------------	---	-----------------	----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60479202 v1

Substitute for form 1449B/PTO				Complete if Known	
				Application Number	09/322,289
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	May 28, 1999
				First Named Inventor	Schenk, Dale B.
				Art Unit	1647
				Examiner Name	Turner, Sharon L.
(use as many sheets as necessary)				Attorney Docket Number	15270J-004740US
Sheet	2	of	4		



NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
S	588	ANDERSON, J. P., "Exact cleavage site of Alzheimer amyloid precursor in neuronal PC-12 cells," <u>Neuroscience Letters</u> , 128(1):126-128 (1991).	
	589	ANDERSON, M. W., "Amending the amyloid hypothesis," <u>The Scientist</u> , 18(20):28-29 (2004).	
	590	BACSKAI et al., "Non-Fc-mediated mechanisms are involved in clearance of amyloid- β in vivo by immunotherapy," <u>J. Neurosci.</u> , 22(18):7873-7878 (2002).	
	591	CHROMY et al., "Self-assembly of A β (1-42) into globular neurotoxins," <u>Biochemistry</u> , 42(44):12749-12760 (2003).	
	592	CITRON et al., "Evidence that the 42- and 40- amino acid forms of amyloid- β protein are generated from the β -amyloid precursor protein by different protease activities," <u>PNAS</u> , 93(23):13170-13175 (1996).	
	593	CITRON, M., "Alzheimer's disease: treatments in discovery and development," <u>Nat. Neurosci.</u> , 5:1055-1057 (2002).	
	594	DEMATOS et al., "Brain to plasma amyloid- β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease," <u>Science</u> , 295(5563):2264-2267 (2002).	
	595	DODART et al., "Immunization reverses memory deficits without reducing brain A β burden in Alzheimer's disease model," <u>Nat. Neurosci.</u> , 5(5):452-457 (2002).	
	596	DODEL et al., "Immunotherapy for Alzheimer's disease," <u>Lancet Neurol.</u> , 2(4):215-220 (2003).	
	597	DOVEY et al., "Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain," <u>J. Neurochem.</u> , 76(1):173-181 (2001).	
	598	DUFF et al., "Increased amyloid- β 42(43) in brains of mice expressing mutant presenilin 1," <u>Nature</u> , 383(6602):710-713 (1996).	
	599	ERIKSEN et al., "NSAIDs and enantiomers of flurbiprofen target γ -secretase and lower A β 42 in vivo," <u>J. Clin. Invest.</u> , 112(3):440-449 (2003).	
	600	FINDEIS, M. A., "Approaches to discovery and characterization of inhibitors of amyloid β -peptide polymerization," <u>Biochem. Biophys. Acta</u> , 1502(1):76-84 (2000).	
S	601	FRENKEL et al., "Reduction of β -amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization," <u>Vaccine</u> , 21(11-12):1060-1065 (2003).	

Examiner Signature		Date Considered	10-27-05
--------------------	---	-----------------	----------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/322,289	
			Filing Date	May 28, 1999	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1647	
			Examiner Name	Turner, Sharon L.	
Sheet	3	of	4	Attorney Docket Number	15270J-004740US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	602	FRENKEL et al., "Towards Alzheimer's β -amyloid vaccination," <u>Biologicals</u> , 29(3-4):243-247 (2001).	
	603	GELINAS et al., "Immunotherapy for Alzheimer's disease," <u>PNAS</u> , 101(suppl. 2):14657-14662 (2004).	
	604	GONG et al., "Alzheimer's disease-affected brain: presence of oligomeric A β ligands (ADDLs) suggests a molecular basis for reversible memory loss," <u>PNAS</u> , 100(18):10417-10422 (2003).	
	605	GREENBERG et al., "Alzheimer disease's double-edged vaccine," <u>Nat. Med.</u> , 9(4):389-390 (2003).	
	606	HAASS, C., "New hope for Alzheimer disease vaccine," <u>Nat Med.</u> , 8(11):1195-1196 (2002).	
	607	HOCK et al., "Generation of antibodies specific for β -amyloid by vaccination of patients with Alzheimer disease," <u>Nat. Med.</u> , 8(11):1270-1275 (2002).	
	608	IRIZARRY et al., "Alzheimer disease therapeutics," <u>J. Neuropathol. Exp. Neurol.</u> , 60(10):923-928 (2001).	
	609	JANUS et al., "Transgenic mouse models of Alzheimer's Disease," <u>Physiol. Behav.</u> , 73(5):873-886 (2001).	
	610	MATTSON et al., "Good and bad amyloid antibodies," <u>Science</u> , 301(5641):1845-1849 (2003).	
	611	MCLAURIN et al., "Therapeutically effective antibodies against amyloid- β peptide target amyloid- β residues and 4-10 and inhibit cytotoxicity and fibrillogenesis," <u>Nat Med.</u> , 8(11):1263-1269 (2002).	
	612	MONSONEGO et al., "Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer's disease," <u>J. Clin. Invest.</u> , 112(3):415-422 (2003).	
	613	MONSONEGO et al., "Immunotherapeutic approaches to Alzheimer's disease," <u>Science</u> , 302(5646):834-838 (2003).	
	614	PAGANETTI et al., "Amyloid precursor protein truncated at any of the γ -secretase sites is not cleaved to β -amyloid," <u>J. Neurosci. Res.</u> , 46(3):283-293 (1996).	
	615	PALLITTO et al., "Recognition sequence design for peptidyl modulators of β -amyloid aggregation and toxicity," <u>Biochemistry</u> , 38(12):3570-3578 (1999).	
	616	PFEIFER et al., "Cerebral hemorrhage after passive anti-A β immunotherapy," <u>Science</u> , 298(5597):1379 (2002).	

Examiner Signature		Date Considered	10-27-05
-----------------------	---	--------------------	----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/322,289	
			Filing Date	May 28, 1999	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1647	
			Examiner Name	Turner, Sharon L.	
Sheet	4	of	4	Attorney Docket Number	15270J-004740US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	626	"Researchers Develop Blood Test to Diagnose Alzheimer's- Type Changes in Mice," downloaded from www.businesswire.com on 12/15/04.	
	617	SCHMID, R. E., "Study suggest Alzheimer vaccine fix," from www.msnbc.com/news, pages 1-5 (2002).	
	618	SELKOE, D. J., "Alzheimer's disease is a synaptic failure," <u>Science</u> , 298(5594):789-791 (2002).	
	622	SERGEANT et al., "Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach," <u>J. Neurochem.</u> , 85(6):1581-1591 (2003).	
	619	SIGURDSSON et al., "Immunization with a nontoxic/nonfibrillar amyloid- β homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice," <u>Am. J. Pathol.</u> , 159(2):439-447 (2001).	
	620	SOLOMON, B., "Generation and brain delivery of anti-aggregating antibodies against β -amyloid plaques using phage display technology," <u>J. Neural Transm. Suppl.</u> , 62:321-325 (2002).	
	621	SOLOMON, B., "Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease," <u>DNA and Cell Biology</u> , 20(11):697-703 (2001).	
	623	WALSH et al., "Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo," <u>Nature</u> , 416(6880):535-539 (2002).	
	624	WASHINGTON UNIVERSITY IN ST. LOUIS SCHOOL OF MEDICINE, "Study gives Clues to Working of Anti-Alzheimer Antibody," downloaded from www.medicine.wustl.edu/~wumpa/news on 12/15/04.	
	625	WHITE et al., "Immunotherapy as a therapeutic treatment for neurodegenerative disorders," <u>J. Neurochem.</u> , 87(4):801-808 (2003).	
	580	ZLOKOVIC et al., "Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers," <u>PNAS</u> , 93(9):4229-4334 (1996) abstract only.	

Examiner Signature		Date Considered	10-27-05
-----------------------	--	--------------------	----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Schenk, Dale B.
Art Unit	1647
Examiner Name	Turner, Sharon L.
Attorney Docket Number	15270J-004740US

[illegible][illegible]

**Examiner
Signature**

Date
Considered

10-27-a

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

2

Complete If Known

Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Schenk, Dale B.
Art Unit	1647
Examiner Name	Turner, Sharon L.
Attorney Docket Number	15270J-004740US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>SD</i>	634	Genbank Accession number AAB48800, "Anti-DNA immunoglobulin light chain IgG [Mus musculus]," 09/14/01.	
	635	Genbank Accession number CAA46659, "IgE antibody light chain(VJ)," 06/15/93.	
	636	Genbank Accession number X65775.1, "M.musculus DNA for IgE antibody light chain (VJ)," 06/15/93.	
	637	Genbank Accession number AAD26773, "Immunoglobulin heavy chain VH3609-JH3 region [Mus musculus]," 04/22/99.	
	628	KOFLER et al., "Mechanism of Allergic Cross-Reactions-III. cDNA Cloning and Variable-Region Sequence Analysis of Two IgE Antibodies Specific for Trinitrophenyl," <u>Mol. Immunology</u> , 29(2):161-166 (1992).	
	627	KRISHNAN et al., "Correlation Between the Amino Acid Position of Arginine in VH-CDR3 and Specificity for Native DNA Among Autoimmune Antibodies ^{1,2} ," <u>J. Immunol.</u> , 157(6):2430-2439 (1996).	
<i>SD</i>	629	SEIDL et al., "Predominant V _H genes expressed in innate antibodies are associated with distinctive antigen-binding sites," <u>PNAS</u> , 96:2262-2267 (1999).	

Examiner
Signature

Date
Considered

10-27-05





*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08B (08-03)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/322,289	
			Filing Date	May 28, 1999	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1647	
			Examiner Name	Turner, Sharon L.	
Sheet	2	of	2	Attorney Docket Number	15270J-004740US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	639	Chimicon International, "Mouse Anti-Amyloid Beta Protein Monoclonal Antibody," Catalog # MAB1561	
	640	JUNG et al., "Alzheimer's Beta-amyloid Precursor Protein Is Expressed on the Surface of Immediately Ex Vivo Brain Cells: a Flow Cytometric Study," <i>J. Neurosci. Res.</i> , 46:336-348 (1996).	
	641	RACKE et al., "Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of amyloid β ," <i>J. Neurosci.</i> , 25(3):629-636 (2005).	
	638	Research Corporation Technology News, "THP and SangStat Partner to Develop Humanized Polyclonal Antibody Drugs," 11/11/02.	

Examiner Signature		Date Considered	10-27-05
-----------------------	---	--------------------	----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.